Praxis Precision Medicines signs Remagine Labs deal for ulixacaltamide transdermal patch
Praxis Precision Medicines entered a research collaboration and license agreement with Remagine Labs to develop an iontophoretic transdermal patch for ulixacaltamide, its essential tremor candidate. The company also made an equity investment in Remagine, and says the transdermal option could broaden the patient population and strengthen the drug's competitive position.
Key points
- Agreement announced July 7, 2026, with Remagine Labs, Inc., a developer of electronically controlled transdermal drug delivery systems
- Remagine's platform is designed for precise, multi-day active transdermal dosing of ulixacaltamide for essential tremor
- Praxis made an equity investment in Remagine; the filing does not disclose the amount or financial terms
- The patch is intended to complement the company's lead oral program for ulixacaltamide
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 07, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.